AdvanCellSenior Scientist, Radiochemical Separations
Richlands, Brisbane, QLD, AU · Full-time
Series D · $315M · 106d ago Posted 3mo ago
Have your AI draft the answers and brief you on AdvanCell→Why join AdvanCell?
Radiation that reaches only the tumor becomes the default cancer treatment, and older therapies start to look dated. AdvanCell, a Sydney radiopharmaceutical developer, is building that with targeted alpha therapies, and owning both development and manufacturing could make it a supplier drug makers rely on. Eli Lilly and Bain Capital Life Sciences sit among the leads on a $315M Series D, bringing its total to $453M across 5 rounds.
JustBacked's take, based on AdvanCell's own site and its funding and hiring data.
The Director of Radiochemical Separations will lead the development, optimisation and execution of radiochemical separation processes supporting the production and recycling of Th-228. The role is responsible for advancing separation technologies from laboratory-scale experimentation through process optimisation, automation and scalable manufacturing implementation.